Inventiva Craters On NASH Safety Scare

 
• By Elizabeth Cairns

An adverse reaction in lanafibranor’s Phase III trial leaves the company even more reliant on the upcoming LEGEND readout.   

Unhappy and disappointed customer giving low rating and negative feedback in survey, poll or questionnaire. Sad and dissatisfied man giving review about service quality. Bad user experience. - Image

More from Clinical Trials

More from R&D